[1] Gorelick PB. Stroke prevention. An opportunity for efficient utilization of health care resources during the coming decade. Stroke 1994;25:220-4.
[2] Mejías-Trueba M, Pérez-Moreno MA, Fernández-Arche MÁ. Systematic review of the efficacy of statins for the treatment of Alzheimer’s disease. Clinical Medicine 2018;18:54.
[3] Cummings JL, Morstorf T, Zhong K. Alzheimer’s disease drug-development pipeline: few candidates, frequent failures. Alzheimer's research & therapy 2014;6:1-7.
[4] Daneschvar HL, Aronson MD, Smetana GW. Do statins prevent Alzheimer's disease? A narrative review. European journal of internal medicine 2015;26:666-9.
[5] Li Q, Zhuang Q, Yang J, Zhang Y. Statins excert neuroprotection on cerebral ischemia independent of their lipid-lowering action: the potential molecular mechanisms. Eur Rev Med Pharmacol Sci 2014;18:1113-26.
[6] Power MC, Weuve J, Sharrett AR, Blacker D, Gottesman RF. Statins, cognition, and dementia—systematic review and methodological commentary. Nature Reviews Neurology 2015;11:220.
[7] McGuinness B, Craig D, Bullock R, Passmore P. Statins for the prevention of dementia. Cochrane Database of Systematic Reviews 2009.
[8] Saravi SSS, Saravi SSS, Arefidoust A, Dehpour AR. The beneficial effects of HMG-CoA reductase inhibitors in the processes of neurodegeneration. Metabolic brain disease 2017;32:949-65.
[9] Levine DA, Langa KM. Vascular cognitive impairment: disease mechanisms and therapeutic implications. Neurotherapeutics 2011;8:361.
[10]Kim SY, Min C, Oh DJ, Choi HG. Tobacco Smoking and Alcohol Consumption Are Related to Benign Parotid Tumor: A Nested Case-Control Study Using a National Health Screening Cohort. Clinical and experimental otorhinolaryngology 2019;12:412.
[11]Kim SY, Min C, Oh DJ, Choi HG. Risk of neurodegenerative dementia in asthma patients: a nested case–control study using a national sample cohort. BMJ open 2019;9:e030227.
[12]Kim SY, Lim J-S, Kong IG, Choi HG. Hearing impairment and the risk of neurodegenerative dementia: a longitudinal follow-up study using a national sample cohort. Scientific reports 2018;8:1-8.
[13]Kim SY, Min C, Oh DJ, Choi HG. Bidirectional association between GERD and asthma: two longitudinal follow-up studies using a national sample cohort. The Journal of Allergy and Clinical Immunology: In Practice 2020;8:1005-13. e9.
[14]Kim SY, Oh DJ, Park B, Choi HG. Bell’s palsy and obesity, alcohol consumption and smoking: A nested case-control study using a national health screening cohort. Scientific reports 2020;10:1-8.
[15]Quan H, Li B, Couris C, Fushimi K, Graham P, Hider P, et al. Practice of epidemiology: updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 2011;173:676-82.
[16]Beydoun MA, Beason-Held LL, Kitner-Triolo MH, Beydoun HA, Ferrucci L, Resnick SM, et al. Statins and serum cholesterol's associations with incident dementia and mild cognitive impairment. J Epidemiol Community Health 2011;65:949-57.
[17]Bettermann K, Arnold AM, Williamson J, Rapp S, Sink K, Toole JF, et al. Statins, risk of dementia, and cognitive function: secondary analysis of the ginkgo evaluation of memory study. Journal of Stroke and Cerebrovascular Diseases 2012;21:436-44.
[18]Haag MD, Hofman A, Koudstaal PJ, Stricker BH, Breteler MM. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. Journal of Neurology, Neurosurgery & Psychiatry 2009;80:13-7.
[19]Cramer C, Haan M, Galea S, Langa K, Kalbfleisch J. Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. Neurology 2008;71:344-50.
[20]Sparks DL, Kryscio RJ, Sabbagh MN, Connor DJ, Sparks LM, Liebsack C. Reduced risk of incident AD with elective statin use in a clinical trial cohort. Current Alzheimer Research 2008;5:416-21.
[21]Foundation. MRCBH. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high‐risk individuals: a randomised placebo‐controlled trial. Lancet 2002;360:7-22.
[22]Shepherd J. Blauw gJ, Murphy MB, et al.; PrOSPer study group. PrOspective Study of Pravastatin in the elderly at risk. Pravastatin in elderly individuals at risk of vascular disease (PrOSPer): a randomised controlled trial. Lancet 2002;360:1623-30.
[23]McGuinness B, Craig D, Bullock R, Passmore P. Statins for the prevention of dementia. Cochrane Database of Systematic Reviews 2016; doi:10.1002/14651858.CD003160.pub3.
[24]Swiger KJ, Manalac RJ, Blumenthal RS, Blaha MJ, Martin SS. Statins and cognition: a systematic review and meta-analysis of short-and long-term cognitive effects. Mayo clinic proceedings: Elsevier; 2013. p. 1213-21.
[25]Ott BR, Daiello LA, Dahabreh IJ, Springate BA, Bixby K, Murali M, et al. Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials. Journal of general internal medicine 2015;30:348-58.
[26]Reitz C, Tang M-X, Luchsinger J, Mayeux R. Relation of plasma lipids to Alzheimer disease and vascular dementia. Archives of neurology 2004;61:705-14.
[27]Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, et al. Inflammation and Alzheimer’s disease. Neurobiology of aging 2000;21:383-421.
[28]Wanamaker BL, Swiger KJ, Blumenthal RS, Martin SS. Cholesterol, statins, and dementia: what the cardiologist should know. Clinical cardiology 2015;38:243-50.
[29]Wang Q, Yan J, Chen X, Li J, Yang Y, Weng J, et al. Statins: multiple neuroprotective mechanisms in neurodegenerative diseases. Experimental neurology 2011;230:27-34.
[30]Tamboli IY, Barth E, Christian L, Siepmann M, Kumar S, Singh S, et al. Statins promote the degradation of extracellular amyloid β-peptide by microglia via stimulation of exosome-associated insulin-degrading enzyme (IDE) secretion. Journal of biological chemistry 2010;285:37405-14.
[31]Refolo LM, Pappolla MA, LaFrancois J, Malester B, Schmidt SD, Thomas-Bryant T, et al. A cholesterol-lowering drug reduces β-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiology of disease 2001;8:890-9.
[32]Simons M, Keller P, Dichgans J, Schulz JB. Cholesterol and Alzheimer’s disease: is there a link? Neurology 2001;57:1089-93.
[33]Bayorh MA, Ganafa AA, Eatman D, Walton M, Feuerstein GZ. Simvastatin and losartan enhance nitric oxide and reduce oxidative stress in salt-induced hypertension. American journal of hypertension 2005;18:1496-502.
[34]Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998;97:1129-35.
[35]Erdös B, Snipes JA, Tulbert CD, Katakam P, Miller AW, Busija DW. Rosuvastatin improves cerebrovascular function in Zucker obese rats by inhibiting NAD (P) H oxidase-dependent superoxide production. American Journal of Physiology-Heart and Circulatory Physiology 2006;290:H1264-H70.
[36]Silva MVF, Loures CdMG, Alves LCV, de Souza LC, Borges KBG, das Graças Carvalho M. Alzheimer’s disease: risk factors and potentially protective measures. Journal of biomedical science 2019;26:33.
[37]Armstrong RA. Risk factors for Alzheimer’s disease. Folia Neuropathol 2019;57:87-105.
[38]Knopman DS, Parisi JE, Boeve BF, Cha RH, Apaydin H, Salviati A, et al. Vascular dementia in a population-based autopsy study. Archives of Neurology 2003;60:569-75.
[39]Jellinger KA. The enigma of vascular cognitive disorder and vascular dementia. Acta neuropathologica 2007;113:349-88.
[40]Korczyn AD. Mixed dementia—the most common cause of dementia. Annals of the New York Academy of Sciences 2002;977:129-34.